These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 27245070)

  • 21. Long-term outcomes in patients with acute coronary syndromes related to prolonging dual antiplatelet therapy more than 12 months after coronary stenting.
    Wimmer NJ; Dufour AB; Cho K; Gagnon DR; Quach L; Ly S; Do JM; Ostrowski S; Michael Gaziano J; Faxon DP; Kinlay S
    Catheter Cardiovasc Interv; 2017 Jun; 89(7):1176-1184. PubMed ID: 27860195
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Duration of Triple Antithrombotic Therapy and Outcomes Among Patients Undergoing Percutaneous Coronary Intervention.
    Koskinas KC; Räber L; Zanchin T; Pilgrim T; Stortecky S; Hunziker L; Blöchlinger S; Billinger M; Gartwyl F; Moro C; Moschovitis A; Jüni P; Heg D; Windecker S
    JACC Cardiovasc Interv; 2016 Jul; 9(14):1473-83. PubMed ID: 27478115
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intracoronary abciximab in diabetic patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Piccolo R; Eitel I; Galasso G; Iversen AZ; Gu YL; Dominguez-Rodriguez A; de Smet BJ; Mahmoud KD; Abreu-Gonzalez P; Thiele H; Piscione F
    Vascul Pharmacol; 2015 Oct; 73():32-7. PubMed ID: 26071862
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contemporary Incidence, Management, and Long-Term Outcomes of Percutaneous Coronary Interventions for Chronic Coronary Artery Total Occlusions: Insights From the VA CART Program.
    Tsai TT; Stanislawski MA; Shunk KA; Armstrong EJ; Grunwald GK; Schob AH; Valle JA; Alfonso CE; Nallamothu BK; Ho PM; Rumsfeld JS; Brilakis ES
    JACC Cardiovasc Interv; 2017 May; 10(9):866-875. PubMed ID: 28473108
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Contraindicated medication use in dialysis patients undergoing percutaneous coronary intervention.
    Tsai TT; Maddox TM; Roe MT; Dai D; Alexander KP; Ho PM; Messenger JC; Nallamothu BK; Peterson ED; Rumsfeld JS;
    JAMA; 2009 Dec; 302(22):2458-64. PubMed ID: 19996401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PCI with and without abciximab after upstream eptifibatide use: outcomes in high-risk patients.
    Applegate RJ; Grabarczyk MA; Sane DC; Sacrinty MT; Goodin JE; Statonk GS; Baki TT; Gandhi SK; Kutcher MA; Little WC
    J Invasive Cardiol; 2006 Dec; 18(12):604-13. PubMed ID: 17197712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of abciximab and eptifibatide on angiographic and clinical outcomes in rescue percutaneous coronary intervention for failed fibrinolytic therapy.
    Bajaj RR; Mohammad A; Hong T; Irfan A; Sharieff W; Bagnall A; Christie JA; Kutryk MJ; Chisholm RJ; Cheema AN
    J Invasive Cardiol; 2010 Aug; 22(8):347-52. PubMed ID: 20679668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of bivalirudin with heparin versus abciximab with heparin for primary percutaneous coronary intervention in "Real World" practice.
    Showkathali R; Davies JR; Parker M; Taggu W; Tang KH; Clesham GJ; Gamma RA; Sayer JW; Aggarwal RK; Kelly PA
    Cardiovasc Revasc Med; 2013; 14(5):289-93. PubMed ID: 23972537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of arterial access site selection on outcomes in primary percutaneous coronary intervention: are the results of randomized trials achievable in clinical practice?
    Mamas MA; Ratib K; Routledge H; Neyses L; Fraser DG; de Belder M; Ludman PF; Nolan J;
    JACC Cardiovasc Interv; 2013 Jul; 6(7):698-706. PubMed ID: 23769648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry.
    Chandrasekhar J; Bansilal S; Baber U; Sartori S; Aquino M; Farhan S; Vogel B; Faggioni M; Giustino G; Ariti C; Colombo A; Chieffo A; Kini A; Saporito R; Michael Gibson C; Witzenbichler B; Cohen D; Moliterno D; Stuckey T; Henry T; Pocock S; Dangas G; Gabriel Steg P; Mehran R
    Catheter Cardiovasc Interv; 2017 Jun; 89(7):E217-E225. PubMed ID: 27650638
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.
    Lincoff AM; Bittl JA; Harrington RA; Feit F; Kleiman NS; Jackman JD; Sarembock IJ; Cohen DJ; Spriggs D; Ebrahimi R; Keren G; Carr J; Cohen EA; Betriu A; Desmet W; Kereiakes DJ; Rutsch W; Wilcox RG; de Feyter PJ; Vahanian A; Topol EJ;
    JAMA; 2003 Feb; 289(7):853-63. PubMed ID: 12588269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Impact of Timing of Ischemic and Hemorrhagic Events on Mortality After Percutaneous Coronary Intervention: The ADAPT-DES Study.
    Brener SJ; Kirtane AJ; Stuckey TD; Witzenbichler B; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Mehran R; Parvataneni R; Brodie BR; Stone GW
    JACC Cardiovasc Interv; 2016 Jul; 9(14):1450-7. PubMed ID: 27372190
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long term efficacy of abciximab bolus-only compared to abciximab bolus and infusion after transradial coronary stenting.
    Bagur R; Bertrand OF; Rodés-Cabau J; Larose E; Rinfret S; Nguyen CM; Noel B; Larochellière RD; Poirier P; Costerousse O; Roy L
    Catheter Cardiovasc Interv; 2009 Dec; 74(7):1010-6. PubMed ID: 19753635
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).
    Kirtane AJ; Parikh PB; Stuckey TD; Xu K; Witzenbichler B; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Brodie BR; Mazzaferri EL; Parvataneni R; Maehara A; Généreux P; Mehran R; Stone GW
    JACC Cardiovasc Interv; 2015 Dec; 8(15):1978-1987. PubMed ID: 26738669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes and costs of abciximab versus eptifibatide for percutaneous coronary intervention.
    Coons JC; Seybert AL; Saul MI; Kirisci L; Kane-Gill SL
    Ann Pharmacother; 2005 Oct; 39(10):1621-6. PubMed ID: 16105872
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Open-label, sequential comparison of eptifibatide with abciximab for patients undergoing percutaneous coronary intervention.
    Schweiger MJ; Changezi HU; Naglieri-Prescod D; Cook JR
    Clin Ther; 2003 Jan; 25(1):225-34. PubMed ID: 12637122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of abciximab in older adults undergoing percutaneous coronary intervention.
    Brown RA; Shantsila E; Varma C; Lip GY
    Int J Clin Pract; 2015 Nov; 69(11):1334-40. PubMed ID: 26202207
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost and effectiveness of glycoprotein IIb/IIIa-receptor inhibitors in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
    McCollam PL; Foster DA; Riesmeyer JS
    Am J Health Syst Pharm; 2003 Jun; 60(12):1251-6. PubMed ID: 12845921
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.
    Gurm HS; Tamhane U; Meier P; Grossman PM; Chetcuti S; Bates ER
    Circ Cardiovasc Interv; 2009 Jun; 2(3):230-6. PubMed ID: 20031720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention.
    Brown DL; Fann CS; Chang CJ
    Am J Cardiol; 2001 Mar; 87(5):537-41. PubMed ID: 11230835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.